Form 4: Precision BioSciences Director Stanley Frankel Reports Stock Vesting
SEC Form 4 Filing
Director Stanley Frankel reported the vesting and settlement of 4,202 Restricted Stock Units (RSUs) into common stock on May 4, 2024.
Summary
- On May 4, 2024, Stanley Frankel, a director of Precision BioSciences, Inc., had 4,202 Restricted Stock Units (RSUs) vest and settle.
- These RSUs converted into 4,202 shares of Precision BioSciences' common stock.
- The RSUs were granted on May 4, 2023, and vested in full on May 4, 2024.
- The reported amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on February 13, 2024.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reporting the vesting of previously granted stock options. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The vesting of RSUs increases the number of outstanding shares, which could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/13/2024 | Precision BioSciences effected a 1-for-30 reverse stock split. |
| 05/04/2023 | Reporting Person was granted RSUs. |
| 05/04/2024 | Restricted Stock Units (RSUs) vested and settled into common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.